Neurotrophic Keratitis MedDRA version: 20.0 Level: PT Classification code 10069732 Term: Neurotrophic keratopathy System Organ Class: 10015919 - Eye disorders
Conditions
Interventions
Product Name: REC 0/0559
Product Code: MT8
Pharmaceutical Form: Eye drops, solution
INN or Proposed INN: not issued
CAS Number: 1458063-51-8
Current Sponsor code: MT-8
Other descriptive name: (1S,4R,
Sponsors
Recordati Rare Diseases
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Be a male or female aged = 18 years 2. Have Stage 2 moderate (PED) or Stage 3 severe (corneal ulcer) NK involving only 1 eye (study eye) and of at least 2 weeks duration. 3. Have no objective clinical evidence of improvement in the PED or corneal ulceration within the 2 weeks before the Screening Visit despite use of conventional non-surgical treatment. 4. Have decreased corneal sensitivity (= 4 cm using the Cochet-Bonnet aesthesiometer) within the area of the PED or corneal ulcer and outside of the area of the defect in at least one corneal quadrant. 5. Have a BCDVA score = 75 ETDRS letters in the study eye, due to NK. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 54 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 54
Exclusion criteria
Exclusion criteria: Individuals meeting any of the following criteria at the Screening Visit are ineligible to participate in this study. For the study eye: 1. Have severe blepharitis and/or severe meibomian gland disease in the study eye. 2. Have severe vision loss in the study eye with no potential for visual improvement in the opinion of the investigator as a result of the study treatment. 3. Have evidence of corneal ulceration/melting involving the posterior third of the corneal stroma, or perforation in the study eye. 4. Have a history of corneal transplantation in the study eye. 5. Have had prior surgical procedures for the treatment of NK (except amniotic membrane transplantation, 6. Have an uncontrolled glaucoma at the Screening Visit 7. Have Stage 2 or 3 NK or perforation. 8. Have had prior treatment with Oxervate (cenegermin eye drops).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: • In the first 24 patients, to determine the safety, tolerability and PK profile of REC 0/0559 (MT8) given as 1 drop 4 times a day (QID) of escalating doses up to 50 µg/mL. • To determine the efficacy and safety of MT8 given as 1 drop QID at 5, 25, and 50 µg/mL during 8 weeks and select the dose with the best benefit risk ratio.;Primary end point(s): The primary endpoint of this study is the percentage of patients achieving complete corneal healing of persistent epithelial defects (PED) or corneal ulcer at Week 8, defined as no corneal fluorescein staining in the area of the PED or corneal ulcer as assessed by an independent central reading centre.;Secondary Objective: Not applicable;Timepoint(s) of evaluation of this end point: week 8 | — |
Secondary
| Measure | Time frame |
|---|---|
| Timepoint(s) of evaluation of this end point: Week 8;Secondary end point(s): • Percentage of patients who achieve a 5-, 10-, and 15-letter mean improvement in best corrected distance visual acuity (BCDVA) by Early Treatment Diabetic Retinopathy Study (ETDRS) chart at Week 8 compared to baseline (in all patients and in patients with a central location of the PED or corneal ulcer, respectively). • Percentage of patients achieving complete corneal healing of PED or corneal ulcer at Week 8, defined as no corneal fluorescein staining in the area of the PED or corneal ulcer as assessed by the investigator. • Time to complete corneal healing of PED or corneal ulcer defined as no corneal fluorescein staining in the area of the PED or corneal ulcer as assessed by an independent central reading. • Time to complete corneal healing of PED or corneal ulcer defined as no corneal fluorescein staining in the area of the PED or corneal ulcer as assessed by the investigator. • Percentage of patients having deterioration of the disease at Week 8 (defined as increase in lesion size = 1 mm as assessed by the investigator, or mean decrease in BCDVA by > 5 letters compared to baseline, or progression in lesion depth to corneal melting or perforation, or onset of infection). • Mean change in BCDVA from baseline to Week 8 in all patients and in patients with a central location of the PED or corneal ulcer, respectively. • Percentage of patients with improvement in corneal sensitivity from baseline as measured by Cochet-Bonnet aesthesiometer at Week 8. | — |
Countries
France, Germany, Hungary, Italy, Spain, United Kingdom, United States
Contacts
Public ContactProject Leader
Recordati Rare Diseases
Outcome results
None listed